Tier 4 — mechanistic

Evolution of a major drug metabolizing enzyme defect in the domestic cat and other Felidae

Shrestha B, Reed JM, Starks PT, Kunz TH, Boston RC, Trepanier LA
PLoS ONE 2011 6(3):e18046

Bibliography

PubMed
PMID 21464924
PubMed Central
PMC3065456
DOI
10.1371/journal.pone.0018046

Study snapshot

DesignComparative molecular genetics study
ModelFelidae species comparison, UGT1A6 gene sequencing
SampleComparative genetic sampling across domestic cats and other Felidae; exact sample count requires consultation of original Methods.
InterventionNot applicable — comparative molecular genetics study; no dosing or treatment.
DurationNot applicable — cross-species genetic analysis, not an intervention or follow-up study.
EndpointsUGT1A6 gene functionality and pseudogenization; Comparative genetic variation in domestic cats and related Felidae; Evolutionary origin of feline glucuronidation deficiency

What the study showed, in plain terms

This study traces the genetic origin of cats' glucuronidation deficiency, showing that the UGT1A6 gene became a non-functional pseudogene early in the evolution of the cat family (Felidae). This explains at a genetic level why domestic cats and their wild relatives are all unusually sensitive to drugs and compounds normally cleared by this pathway.

Key findings

UGT1A6 is pseudogenised (non-functional) across all Felidae species tested, not just domestic cats — an ancient evolutionary loss, not a modern breed-specific trait. Does not test fisetin or any flavonoid specifically.

What this study can and cannot tell us

Molecular/genetic study, not a pharmacokinetic or safety trial. Does not address fisetin or flavonoid exposure in cats directly — use only to explain the underlying genetic mechanism.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability